Roberto Labianca

Also affiliated with Ospedale Papa Giovanni XXIII

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer”.

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer

The Lancet(1998)10.1016/s0140-6736(98)03085-2

N/A

1.0DataRank · unranked

993 citations

Eric Van Cutsem, Emilio Bajetta, Norbert Niederle, Kurt Possinger, Roberto Labianca +8 more

Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4004

N/A

0DataRank · unranked

36 citations

Thierry André, Jeffrey A. Meyerhardt, Axel Grothey, Timothy Iveson, Takayuki Yoshino +15 more